INTS
Intensity Therapeutics, Inc. Common stockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$12.73M
P/E Ratio
—
EPS
$-4.01
Beta
3.26
52W High
$43.50
52W Low
$4.50
50-Day MA
$5.43
200-Day MA
$7.98
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc. is an innovative biotechnology company dedicated to transforming cancer treatment through its state-of-the-art drug delivery systems. The company's focus on enhancing the efficacy of immuno-oncology therapies while minimizing systemic side effects addresses significant unmet needs in the oncology sector. With a strong emphasis on advanced research and development, Intensity Therapeutics is poised to lead advancements in targeted therapies that bolster the body's immune response against cancer, ultimately aiming to improve patient outcomes in a complex and evolving medical landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -207.40% |
| Return on Assets | -90.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.70 |
| Price-to-Book | 1.26 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -4.72 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $2.70M |
| Float | $2.47M |
| % Insiders | 4.55% |
| % Institutions | 6.19% |
Historical Volatility
HV 10-Day
38.35%
HV 20-Day
28.15%
HV 30-Day
25.09%
HV 60-Day
47.25%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($24.80 target)
6
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026